Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Protocol Approved: 10/11/24 | Other Identifier | UW Madison | |
| A534265 | Other Identifier | UW Madison | |
| BFD-RST-23-010 | Other Identifier | Sponsor Protocol ID |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| BioMérieux | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate where urgent care (UC) clinicians see the most benefit for a novel, point of care pharyngitis test, SPOTFIRE ST, and describe its performance, potential clinical utility, and satisfaction of providers and patients with this novel test. Up to 200 participants will be on study for up to approximately 25 minutes.
The broader study is separated into three specific aims.
AIM 1. Evaluate which specific patient populations UC providers see the most need and benefit from SPOTFIRE ST, a multiplex point of care pharyngitis test (preparatory for the clinical trial, included here for context only).
AIM 2. Evaluate the performance and effects of test results associated with important clinical outcomes (e.g., prescriptions, additional testing, disposition and follow-up) for patients in the top 3-4 high-risk subpopulations identified by providers in Specific AIM 1.
AIM 3. Evaluate patient and provider satisfaction and future use opportunities of the SPOTFIRE ST Panel testing platform in the clinical pathway for evaluating patients with pharyngitis in UC centers.
AIMS 2-3 are registered to this ClinicalTrials.gov record.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eligible SPOTFIRE ST Participants | Experimental | A maximum of 200 patients, representing the top 3-4 patient groups that were identified as benefitting most from a SPOTFIRE ST test through the provider survey, presenting at the Urgent Care facilities, will be enrolled. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SPOTFIRE ST System | Device | Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Aim 2 Clinical Outcome: Summary of Test Results | SPOTFIRE ST results by count. | up to 20 minutes |
| Aim 2 Clinical Outcome: Number of Participants With Follow up Testing | Data collected via electronic medical record review 3 weeks post study visit. | up to 3 weeks |
| Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: Rapid Flu vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | up to 3 weeks |
| Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: Rapid Respiratory Syncytial Virus (RSV) vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | up to 3 weeks |
| Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: COVID PCR vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | up to 3 weeks |
| Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: Rapid Strep Antigen vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | up to 3 weeks |
| Aim 2 Clinical Outcome: Summary of Resultant Prescriptions: Participants With Treatable Pathogens | SPOTFIRE ST resultant prescriptions by count. Data collected via electronic medical record review 3 weeks post study visit. Treatable Pathogens include: Influenza A or B (FluA/B), Group A Strep (GAS), Mycoplasma pneumoniae (Mpn), Chlamydia pneumoniae (Cpn) |
Not provided
Not provided
Inclusion Criteria:
Illness onset in the last 7 days, AND:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexander Lepak, MD | UW School of Medicine and Public Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UW Health Urgent Care Centers | Madison | Wisconsin | 53717 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
371 participants were screened for enrollment into the study, 232 were found eligible, and 200 enrolled. Most participants declined enrollment because they were not interested or feeling too sick to participate.
Participants were consented and enrolled from December 2024 to March 2025.
Providers were not formally consented, their survey response was voluntary. Provider participation was preparatory to research only and was deemed Program Evaluation pursuant to 45 Code of Federal Regulations (CFR) 46.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Eligible SPOTFIRE ST Participants | A maximum of 200 patients, representing the top 3-4 patient groups that were identified as benefitting most from a SPOTFIRE ST test through the provider survey, presenting at the Urgent Care facilities, will be enrolled. SPOTFIRE ST System: Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Eligible SPOTFIRE ST Participants | A maximum of 200 patients, representing the top 3-4 patient groups that were identified as benefitting most from a SPOTFIRE ST test through the provider survey, presenting at the Urgent Care facilities, will be enrolled. SPOTFIRE ST System: Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Aim 2 Clinical Outcome: Summary of Test Results | SPOTFIRE ST results by count. | Posted | Count of Participants | Participants | up to 20 minutes |
|
|
up to 3 weeks
3 week follow up data was collected from medical records
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Eligible SPOTFIRE ST Participants | A maximum of 200 patients, representing the top 3-4 patient groups that were identified as benefitting most from a SPOTFIRE ST test through the provider survey, presenting at the Urgent Care facilities, will be enrolled. SPOTFIRE ST System: Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Alexander Lepak, MD, FIDSA | University of Wisconsin School of Medicine and Public Health | (608) 263-1545 | ajlepak@medicine.wisc.edu |
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jun 20, 2024 | Jan 27, 2026 | Prot_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010612 | Pharyngitis |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D010608 | Pharyngeal Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| up to 3 weeks |
| Aim 2 Clinical Outcome: Summary of Resultant Prescriptions: Participants With Viral Pathogens Prescribed Antibiotics | SPOTFIRE ST resultant prescriptions by count. Data collected via electronic medical record review 3 weeks post study visit. | up to 3 weeks |
| Aim 3: Participant Satisfaction Survey | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to approximately 4 months) |
| Aim 3: Participant Satisfaction Survey - How do the Results Feel? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Participant Satisfaction Survey - Are You Satisfied With the Test Result? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Participant Satisfaction Survey - Are You Satisfied With Provider Information? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Participant Satisfaction Survey - Are You Satisfied With the Treatment? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Participant Satisfaction Survey - How Useful is the Test in Understanding Your Illness? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Participant Satisfaction Survey - Likelihood to do Test Again? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Utility Survey | Providers will be surveyed to learn how they might use the SPOTFIRE test in the future. Survey responses will be ranked and reported by response rate. Providers were asked to rank each patient population from 1-7, a nominal point value was given for this ranking to generate the scores (rank of 1=1, rank of 2=2, etc.) Lower scores indicate higher (more important) ranking. Mean rank score for each patient population is reported here to give the reader an idea of how important each item was for the group of providers. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - How Often Test Used? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - Ease of Fitting Into Workflow? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - How Prepared Did You Feel to Answer Questions About Test? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey -Test Differed From Initial Clinical Impression? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - How Useful Was the Test? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - To What Extent is This Panel Useful Over Having Just Rapid Antigen Tests (RAT) for Group A Strep (GAS)? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - How Often do You Think This Test Helped You Rx Abx/AV More Judiciously? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. Prescription for Antibiotics or Antivirals (Rx Abx/AV) | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - How Often do You Think You Would Use SPOTFIRE if Clinically Available All the Time? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| Aim 3: Provider Satisfaction Survey - When do You Think it Would be Best to Test Patients With SPOTFIRE? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
| years |
|
| Sex/Gender, Customized | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Includes counts for more than one race in their respective categories | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Age Group | Count of Participants | Participants |
|
| Recruitment Group | Count of Participants | Participants |
|
| Attend School | Count of Participants | Participants |
|
| Attend Daycare | Count of Participants | Participants |
|
| Attend Work | Count of Participants | Participants |
|
| Tobacco | Count of Participants | Participants |
|
| Days of Illness Prior to Presentation | Mean | Standard Deviation | days |
|
| Severity of Illness | Count of Participants | Participants |
|
| Reported Exposure to someone else ill | Count of Participants | Participants |
|
| Flu Vaccine (current year) | Count of Participants | Participants |
|
| Coronavirus (COVID) Vaccine within the last 12 months | Count of Participants | Participants |
|
| Symptoms | Count of Participants | Participants |
|
|
|
| Primary | Aim 2 Clinical Outcome: Number of Participants With Follow up Testing | Data collected via electronic medical record review 3 weeks post study visit. | Posted | Count of Participants | Participants | up to 3 weeks |
|
|
|
| Primary | Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: Rapid Flu vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | Participants who follow had follow up with Rapid Flu Test | Posted | Count of Participants | Participants | up to 3 weeks |
|
|
|
| Primary | Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: Rapid Respiratory Syncytial Virus (RSV) vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | Participants who follow had follow up with Rapid RSV Test | Posted | Count of Participants | Participants | up to 3 weeks |
|
|
|
| Primary | Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: COVID PCR vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | Participants who follow had follow up with COVID PCR Test | Posted | Count of Participants | Participants | up to 3 weeks |
|
|
|
| Primary | Aim 2 Clinical Outcome: Number of Participants With Follow up Testing: Rapid Strep Antigen vs SPOTFIRE Results | Data collected via electronic medical record review 3 weeks post study visit. | Participants who follow had follow up with Rapid Strep Antigen Test | Posted | Count of Participants | Participants | up to 3 weeks |
|
|
|
| Primary | Aim 2 Clinical Outcome: Summary of Resultant Prescriptions: Participants With Treatable Pathogens | SPOTFIRE ST resultant prescriptions by count. Data collected via electronic medical record review 3 weeks post study visit. Treatable Pathogens include: Influenza A or B (FluA/B), Group A Strep (GAS), Mycoplasma pneumoniae (Mpn), Chlamydia pneumoniae (Cpn) | Number analyzed documents the number of participants diagnosed in each sub-group. | Posted | Count of Participants | Participants | up to 3 weeks |
|
|
|
| Primary | Aim 2 Clinical Outcome: Summary of Resultant Prescriptions: Participants With Viral Pathogens Prescribed Antibiotics | SPOTFIRE ST resultant prescriptions by count. Data collected via electronic medical record review 3 weeks post study visit. | Number analyzed documents the number of participants diagnosed in each sub-group. | Posted | Count of Participants | Participants | up to 3 weeks |
|
|
|
| Primary | Aim 3: Participant Satisfaction Survey | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | Number analyzed changes to illustrate sub-populations. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to approximately 4 months) |
|
|
|
| Primary | Aim 3: Participant Satisfaction Survey - How do the Results Feel? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | Of participants who completed the survey | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Participant Satisfaction Survey - Are You Satisfied With the Test Result? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | Of participants who completed the survey, data missing from 1 participant | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Participant Satisfaction Survey - Are You Satisfied With Provider Information? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | Of participants who completed the survey | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Participant Satisfaction Survey - Are You Satisfied With the Treatment? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | Of participants who completed the survey | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Participant Satisfaction Survey - How Useful is the Test in Understanding Your Illness? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | Of participants who completed the survey | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Participant Satisfaction Survey - Likelihood to do Test Again? | Participant Satisfaction will be measured using a self-report survey for satisfaction with the testing experience. | Of participants who completed the survey, data missing from 1 participant | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Utility Survey | Providers will be surveyed to learn how they might use the SPOTFIRE test in the future. Survey responses will be ranked and reported by response rate. Providers were asked to rank each patient population from 1-7, a nominal point value was given for this ranking to generate the scores (rank of 1=1, rank of 2=2, etc.) Lower scores indicate higher (more important) ranking. Mean rank score for each patient population is reported here to give the reader an idea of how important each item was for the group of providers. | Providers not enrolled as their participation was considered program evaluation. Some voluntarily completed surveys before and after testing patients. | Posted | Number | rank order score | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - How Often Test Used? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | All providers who voluntarily completed surveys after patient testing. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - Ease of Fitting Into Workflow? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Post-Hoc | Pathogen Detections for Viral and Bacterial Pathogens | A separate analysis looking at pathogen detections for viral and bacterial pathogens was performed. | Posted | Count of Participants | Participants | up to 20 minutes |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - How Prepared Did You Feel to Answer Questions About Test? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey -Test Differed From Initial Clinical Impression? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - How Useful Was the Test? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - To What Extent is This Panel Useful Over Having Just Rapid Antigen Tests (RAT) for Group A Strep (GAS)? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - How Often do You Think This Test Helped You Rx Abx/AV More Judiciously? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. Prescription for Antibiotics or Antivirals (Rx Abx/AV) | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - How Often do You Think You Would Use SPOTFIRE if Clinically Available All the Time? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| Primary | Aim 3: Provider Satisfaction Survey - When do You Think it Would be Best to Test Patients With SPOTFIRE? | Provider Satisfaction will be measured using a self-report survey to indicate satisfaction with the testing experience. | The providers who used SPOTFIRE and answered the question. | Posted | Count of Participants | Participants | emailed after SPOTFIRE testing, survey data collected from all participants through the end of the study (up to 4 months) |
|
|
|
| 0 |
| 200 |
| 0 |
| 200 |
| 0 |
| 200 |
Not provided
Not provided
Not provided
| D012140 |
| Respiratory Tract Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| Title | Measurements |
|---|---|
|
| Rapid Strep Antigen test |
|
| Influenza detected and prescribed antiviral |
|
|
| Treatable bacterial pathogen detection and prescribed antibiotic (GAS, Mpn, Cpn) |
|
|
| SPOTFIRE negative |
|
|
| SPOTFIRE single virus |
|
|
| SPOTFIRE multiple viruses |
|
|
|
| Took Test before Visit |
|
|
| Liked Testing before Visit |
|
|
| Slightly Relieved |
|
| Not Relieved |
|
| Slightly Satisfied |
|
| Not Satisfied |
|
| Slightly Satisfied |
|
| Not Satisfied |
|
| Slightly Satisfied |
|
| Not Satisfied |
|
| Slightly Useful |
|
| Not Useful |
|
| Slightly Likely |
|
| Not Likely |
|
| Preschool and school aged children (3-17 years) with acute pharyngitis symptoms |
|
| Toddlers (1-2 years) with febrile illness (may or may not be able to report pharyngitis symptoms) |
|
| Infants (less than 12 months) with acute febrile illness |
|
| Patients with chronic medical comorbidities with acute pharyngitis symptoms |
|
| Patient with immunocompromising conditions or medications with acute pharyngitis symptoms |
|
| Never |
|
| Difficult |
|
| Very Difficult |
|
| Positive for single bacteria |
|
| Positive for multiple bacteria |
|
| Positive for virus and bacterial pathogens |
|
| Nothing detected |
|
| Slightly Prepared |
|
| Not Prepared |
|
| Never |
|
| Slightly Useful |
|
| Not Useful |
|
| Slightly Useful |
|
| Not Useful |
|
| Rarely |
|
| Never |
|
| Rarely |
|
| Never |
|